Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9112626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1568-5608 (Electronic) Linking ISSN: 09254692 NLM ISO Abbreviation: Inflammopharmacology Subsets: MEDLINE
    • Publication Information:
      Publication: Basel ; Boston : Birkhäuser
      Original Publication: Dordrecht, The Netherlands ; Norwell, MA, USA : Kluwer Academic Publishers, c1991-
    • Subject Terms:
    • Abstract:
      1. A strategy is described for evaluating drugs against different phases in the development of an auto allergic disease, experimental allergic encephalomyelitis. It is based on a cell transfer technique whereby the disease is passively transferred with lymphoid cells from actively immunized donor rats to normal syngeneic rats = passive recipients. Drugs may be applied in vivo to either the cell donors or the cell recipients or to cells in vitro whilst in transit; their efficiency being determined by the severity of the passive disease (weight loss, paralysis) in the recipients. 2. Examples are given illustrating the application of these techniques to: (a) evaluating the lymphocyte-deactivating activity of various nitrogen mustards in vitro; (b) recognizing drugs, e.g. gold derivatives, clofazimine, etc. that are not conventional immunosuppressant (or cytostatic) agents which, when given to the recipient animals, may prevent the expression of the adopted disease; (c) comparing some known immunosuppressants for potency, duration of action, etc.; (d) demonstrating the versatility of cycloleucine, ICI-47,776, etc. 3. Some merits of the strategy are discussed vis a vis using the local graft-versus-host reaction in rats to search for new drugs.
    • References:
      Albert A (1973) Selective Toxicity, 5th edn. Chapman and Hall, London. (PMID: 10.1007/978-1-4899-7130-2)
      Baxter AG (2007) The origin and application of experimental autoimmuno encephalomyelitis. Nature Rev Immunol 7:904–912. (PMID: 10.1038/nri2190)
      Beck FJ, Levy L, Whitehouse MW (1973) The local graft versus host reaction in the rat as a tool for drug mechanism studies. Brit J Pharmacol 49:293–302. (PMID: 10.1111/j.1476-5381.1973.tb08375.x)
      Broadley SA, Barnett MH, Boggild M et al (2015) A new era in the treatment of multiple sclerosis. Med J Austr 203:139–141. (PMID: 10.5694/mja14.01218)
      Cock IE, Cheesman MJ (2018) The potential of plants of the genus Syzygium (Myrtaceae) for the prevention and treatment of arthritic and autoimmune diseases IN Bioactive foods as dietary interventions for arthritis, osteoarthritis, and related autoimmune diseases, 2nd edn. (Eds VR Preedy, RR Watson), Elsevier, Cambridge.
      Constantinescu CS, Farooqi N, O’Brien K, Gran B (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis(MS). Br J Pharmacol 164:1079–1106. (PMID: 10.1111/j.1476-5381.2011.01302.x)
      Currey HLF, Fowler PD (1972) A study of clofazimine in the rat. Brit J Pharmacol 65:676–681. (PMID: 10.1111/j.1476-5381.1972.tb08126.x)
      Davies GE (1968) Immunosuppressive activity of 3-acetyl-5(4-fluoro benzylidene)-hydroxy-2-oxo-2:5-dihyrothiophen (ICI-47,776). Immunol 14:393–399.
      Franklin TJ, Newbould BB, O’Mant DM, Scott AI, Stacey GJ, Davies GE (1966) A new type of cytotoxic immunosuppressant agent: 3-acetyl-5 (4-fluorobenzylidene)-4-hydroxy-2-oxo-2:5 dihydrothiophen. Nature 210:638–639. (PMID: 10.1038/210638a0)
      Denic A, Johnson AJ, Bieber AJ, Warrington AE et al (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18:21–29. (PMID: 10.1016/j.pathophys.2010.04.004)
      Ebringer A (2015) Multiple Sclerosis ‘Mad Cow Disease’ and Acinetobacter. Springer, London. (PMID: 10.1007/978-3-319-02735-7)
      Friedman M, Krull LH, Cavins JF (1970) The chromatographic determination of cysteine and half-cysteine residues in proteins as S- -(4-pyridytlethyl)-L-cysteine. J Biol Chem 245:3868–3871. (PMID: 10.1016/S0021-9258(18)62930-8)
      Gerber RC, Orr KJ, Whitehouse MW (1972) Effect of gold preparations on the development and passive transfer of experimental allergic encephalomyelitis in rats. Proc Soc Exp Biol Med 140:1379–1384. (PMID: 10.3181/00379727-140-36678)
      Ghosh PB, Whitehouse MW (1969) Potential antileukemic and immunosuppressive drugs II. Further studies with Benzo-2,1,3-oxadiazoles and their N-oxides. J Med Chem 12:505–507. (PMID: 10.1021/jm00303a606)
      Lassman H (2018) Experimental models of multiple sclerosis. Sci Rep 8:13628. https://doi.org/10.1038/s4159-018-31957-7. (PMID: 10.1038/s4159-018-31957-7)
      Levine S, Wenk EJ (1965) A hyperacute form of allergic encephalomyelitis. Am J Path 47:61–88. (PMID: 14308139)
      Mandeville A, Cock IE (2018) Terminalia chebula food extracts inhibit bacterial triggers for some autoimmune diseases. Ind J Microbiol 58:496–506. (PMID: 10.1007/s12088-018-0754-9)
      Mehrishi JN, Grassetti DR (1969) Sulphydryl groups on the surface of intact Ehrlich ascites tumour cells, human blood platelets and lymphocytes. Nature 224:563–564. (PMID: 10.1038/224563a0)
      Newbould BB (1965) Production of allergic encephalomyelitis in rats by injection of spinal cord adjuvant into the inguinal lymph nodes. Immunology 56:613–614.
      Newbould BB, Pearson CM, Van de Sande B (1969) Effect of immunosuppression on allergic encephalomyelitis in rats and of immunosuppressive drugs on the cell-mediated transfer of the disease. Arthr Rheum 12:683.
      Paterson PY (1960) Transfer of allergic encephalomyelitis in rats by means of lymph node cells. J Exp Med 111:119–135. (PMID: 10.1084/jem.111.1.119)
      Paterson PY (1966) Experimental allergic encephalomyelitis and auto-immune disease. Adv Immunol 5:131–218. (PMID: 10.1016/S0065-2776(08)60273-4)
      Paterson PY (1968) Experimental auto-immune allergic encephalomyelitism. In: Miescher PA, Muller-Eberhar HJ (eds) Textbook of Immunopathology. Grune and Stratton, New York, pp 132–149.
      Paterson PY, Drobish DG (1969) Cyclophosphamide: effect on experimental allergic encephalomyelitis in Lewis rats. Science 106:191–192. (PMID: 10.1126/science.165.3889.191)
      Paterson PY, Hanson MA (1969) Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats. J Immunol 103:1311–1316. (PMID: 5361567)
      Rosenthale ME (1974) Evaluation for immunosuppressant and anti-allergic activity. In: Scherrer RA, Whitehouse MW (eds) Anti-Inflammatory Agents. Academic Press, New York, pp 123–192. (PMID: 10.1016/B978-0-12-623902-7.50010-4)
      Rosenthale ME, Datko LJ, Kasserich J, Schneider F (1969) Chemotherapy of experimental allergic encephalomyelitis (EAE). Arch int Pharmacodyn 179:251–275. (PMID: 5367302)
      Rosenthale ME, Atko LJ, Kasserich J, Rosanoff EL (1972) Immunopharmacologic effects of cycloleucine. J Pharmacol exptl Therap 180:501–513.
      Samter M (ed) (1971) Immunological diseases. Little Brown, Boston.
      Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM et al (2016) Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci USA 113:4777–4782. (PMID: 10.1073/pnas.1603907113)
      Sirdaata J, Mathews B, White A, Cock IE (2015) GC-MS and LC-MS analysis of Kakadu plum fruit extracts displaying inhibitory activity against microbial triggers of multiple sclerosis. Pharmacog Commn 5:100–115. (PMID: 10.5530/pc.2015.2.2)
      Smith SB, Waksman BH (1969) Passive transfer and labelling studies on the cell infiltrates in experimental allergic encephalomyelitis. J Pathol 23:237–244. (PMID: 10.1002/path.1710990307)
      Udenfriend S, Clark CT, Axelrod J, Brodie BB (1954) Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 208:731–739. (PMID: 10.1016/S0021-9258(18)65598-X)
      Whitehouse MW (1971) Biochemical studies of flumefenine. HC1 (R-760 Flazalone), a new anti-inflammatory drug. Proc W Parmacol Soc 6:55–57.
      Whitehouse MW, Doskotch RW (1969) Selective inhibition of thymidine incorporation into lymphocytes by cucurbitacins B and D. Biochem Pharmacol 18:1790–1793. (PMID: 10.1016/0006-2952(69)90174-9)
      Whitehouse DJ, Whitehouse MW, Pearson CM (1969) Passive transfer of adjuvant-induced arthritis and allergic encephalomyelitis in rats using thoracic duct lymphocytes. Nature 224:1322. (PMID: 10.1038/2241322a0)
      Whitehouse MW, Droge MM, Struck RF (1972) Potential immunosuppressant activity of cyclophosphamide metabolites. Abstr Int Congr Pharmacol 5:251.
      Whitehouse MW, Levy L, Beck FJ (1973) Effect of cyclophosphamide on a local graft-versus-host reaction in the rat: influence of sex, disease and different dosage regimens. Agents Act 3:53–60. (PMID: 10.1007/BF02023854)
      Whitehouse MW, Orr KJ, Beck FJ, Pearson CM (1974) Freund’s adjuvants: relationship of arthritogenicity and adjuvanticity in rats to vehicle composition. Immunol 27:311–330.
      Yu DTY, Whitehouse MW (1973) Effect of some nitrogen mustards and thoracic duct drainage on lymphocyte distribution in rats. Int Arch Allergy Appl Immunol 46:172–182. (PMID: 10.1159/000231121)
    • Contributed Indexing:
      Keywords: Drug evaluation against PL; Experimental allergic encephalomyelitis (EAE); Multiple sclerosis (MS); Pathophoric lymphocytes (PL)
    • Accession Number:
      0 (Immunosuppressive Agents)
    • Publication Date:
      Date Created: 20190220 Date Completed: 20211105 Latest Revision: 20211105
    • Publication Date:
      20231215
    • Accession Number:
      10.1007/s10787-019-00565-w
    • Accession Number:
      30778876